5/2/2024

Janusmed kön och genus

Janusmed kön och genus – oseltamivir

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C C
C C

Oseltamivir

Oseltamivir

Klass : C

Visa all info

Skriv ut

Kontakta oss

  1. Shi J, Wang X, Eyler RF, Liang Y, Liu L, Mueller BA et al. Association of Oseltamivir Activation with Gender and Carboxylesterase 1 Genetic Polymorphisms. Basic Clin Pharmacol Toxicol. 2016;119(6):555-561.

  2. Maltezou HC, Drakoulis N, Siahanidou T, Karalis V, Zervaki E, Dotsikas Y et al. Safety and pharmacokinetics of oseltamivir for prophylaxis of neonates exposed to influenza H1N1. Pediatr Infect Dis J. 2012;31(5):527-9.

  3. Wang CB, Chiu ML, Lin PC, Liang WM, Chen CY, Chang YJ et al. Prompt Oseltamivir Therapy Reduces Medical Care and Mortality for Patients With Influenza Infection: An Asian Population Cohort Study. Medicine (Baltimore). 2015;94(27):e1070.

  4. Bettis R, Iacuzio D, Jung T, Fuchs R, Aultman R, Gyldmark M. Impact of influenza treatment with oseltamivir on health, sleep and daily activities of otherwise healthy adults and adolescents. Clin Drug Investig. 2006;26(6):329-40.

  5. Blanchon T, Mentré F, Charlois-Ou C, Dornic Q, Mosnier A, Bouscambert M et al. Factors associated with clinical and virological response in patients treated with oseltamivir or zanamivir for influenza A during the 2008-2009 winter. Clin Microbiol Infect. 2013;19(2):196-203.

  6. Duval X, van der Werf S, Blanchon T, Mosnier A, Bouscambert-Duchamp M, Tibi A et al. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med. 2010;7(11):e1000362.

  7. Choo D, Hossain M, Liew P, Chowdhury S, Tan J. Side effects of oseltamivir in end-stage renal failure patients. Nephrol Dial Transplant 2011 Jul;26(7):2339-44

  8. Casscells SW, Granger E, Kress AM, Linton A. The association between oseltamivir use and adverse neuropsychiatric outcomes among TRICARE beneficiaries, ages 1 through 21 years diagnosed with influenza. Int J Adolesc Med Health. 2009;21(1):79-89.

  9. Ueda N, Umetsu R, Abe J, Kato Y, Nakayama Y, Kato Z et al. Analysis of Neuropsychiatric Adverse Events in Patients Treated with Oseltamivir in Spontaneous Adverse Event Reports. Biol Pharm Bull. 2015;38(10):1638-44.

  10. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2022 [cited 2023-03-02.]

  11. GUPS. Stockholm: Region Stockholm. 2022 [cited 2023-06-20.]

  1. Shi J, Wang X, Eyler RF, Liang Y, Liu L, Mueller BA et al. Association of Oseltamivir Activation with Gender and Carboxylesterase 1 Genetic Polymorphisms. Basic Clin Pharmacol Toxicol. 2016;119(6):555-561.
  2. Maltezou HC, Drakoulis N, Siahanidou T, Karalis V, Zervaki E, Dotsikas Y et al. Safety and pharmacokinetics of oseltamivir for prophylaxis of neonates exposed to influenza H1N1. Pediatr Infect Dis J. 2012;31(5):527-9.
  3. Wang CB, Chiu ML, Lin PC, Liang WM, Chen CY, Chang YJ et al. Prompt Oseltamivir Therapy Reduces Medical Care and Mortality for Patients With Influenza Infection: An Asian Population Cohort Study. Medicine (Baltimore). 2015;94(27):e1070.
  4. Bettis R, Iacuzio D, Jung T, Fuchs R, Aultman R, Gyldmark M. Impact of influenza treatment with oseltamivir on health, sleep and daily activities of otherwise healthy adults and adolescents. Clin Drug Investig. 2006;26(6):329-40.
  5. Blanchon T, Mentré F, Charlois-Ou C, Dornic Q, Mosnier A, Bouscambert M et al. Factors associated with clinical and virological response in patients treated with oseltamivir or zanamivir for influenza A during the 2008-2009 winter. Clin Microbiol Infect. 2013;19(2):196-203.
  6. Duval X, van der Werf S, Blanchon T, Mosnier A, Bouscambert-Duchamp M, Tibi A et al. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med. 2010;7(11):e1000362.
  7. Choo D, Hossain M, Liew P, Chowdhury S, Tan J. Side effects of oseltamivir in end-stage renal failure patients. Nephrol Dial Transplant 2011 Jul;26(7):2339-44
  8. Casscells SW, Granger E, Kress AM, Linton A. The association between oseltamivir use and adverse neuropsychiatric outcomes among TRICARE beneficiaries, ages 1 through 21 years diagnosed with influenza. Int J Adolesc Med Health. 2009;21(1):79-89.
  9. Ueda N, Umetsu R, Abe J, Kato Y, Nakayama Y, Kato Z et al. Analysis of Neuropsychiatric Adverse Events in Patients Treated with Oseltamivir in Spontaneous Adverse Event Reports. Biol Pharm Bull. 2015;38(10):1638-44.
  10. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2022 [cited 2023-03-02.]
  11. GUPS. Stockholm: Region Stockholm. 2022 [cited 2023-06-20.]